Skip to content
Markets News
Stocks1 min read

Orion Trial Reports Lower Prostate Cancer Metastasis Risk With Darolutamide

Makkler Newsroom
October 24, 2026 · Based on reporting by GlobeNewswire

An interim Phase 3 analysis found a 58% lower risk of metastasis or death when darolutamide was added to standard treatment.

Key takeaways

  • Darolutamide plus ADT and radiation cut the trial’s risk of metastasis or death by 58%.
  • Four-year metastasis-free survival was 95% with darolutamide and 88% with placebo.

Orion said an interim Phase 3 analysis found that darolutamide, added to androgen deprivation therapy (ADT) and radiation, reduced the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence. The results will be presented at the European Society for Medical Oncology Congress.

After a median follow-up of 3.8 years, four-year metastasis-free survival was 95% among patients receiving darolutamide, compared with 88% for those given placebo. The trial’s secondary results included a 53% reduction in the risk of prostate-specific antigen progression, according to Orion.

Grade 3 or higher adverse events occurred in 43% of patients receiving darolutamide and 36% in the placebo group. Darolutamide is not approved for this treatment setting, and follow-up is continuing to assess longer-term outcomes, including overall survival.

Topics
ORNAVNubeqa
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.